The authors recommend assessment of bone status at commencement and during anastrozole therapy and call for further assessment of the use of bisphosphonates to prevent bone loss in these patients.

Bisphosphonates are the mainstay of osteoporosis therapy. Extensive clinical evaluation supports their utility in stemming progression of the disease and in reducing fracture risk. In the course ...

and so in 2023 we released a database of drugs that allows scientists to narrow their search from a list of 7,817 potential candidates to a 'top 214.' We also screened 1,992 bisphosphonates in ...